IDYA

IDEAYA Biosciences, Inc. | Cotação de Ações

Última atualização22/04/2025, 11:33:27

PreçoUS$ 18,26

Variação (dia)US$ 0,08 (0.41%)▲

Min. 52 SemanasUS$ 13,45

Máx. 52 SemanasUS$ 44,42

Capitalização de mercado--

Endereço: 5000 Shoreline Court, South San Francisco, CA, 94080

Telefone: 650 443 6209

Funcionários: 131

IDEAYA Biosciences, Inc.IDYA

US$ 18,26

+ 0,0750,41%

22/04/2025 11:33:27

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 18,26

Valor de mercado--

AberturaUS$ 16,75

Preço máximoUS$ 18,55

Preço mínimoUS$ 18,15

VolumeUS$ 127 mil

Fechamento anteriorUS$ 18,18

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Ações relacionadas

Crinetics Pharmaceuticals, Inc.

CRNX ▲0.04% | US$ 38,25

Bicycle Therapeutics plc

BCYC ▼0.04% | US$ 13,00

Merus N.V.

MRUS ▼0.15% | US$ 40,25

Replimune Group, Inc.

REPL ▲0.04% | US$ 13,73

SpringWorks Therapeutics, Inc.

SWTX ▲0.39% | US$ 36,21

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Encontre respostas para suas dúvidas sobre investimentos em nossa seção de Perguntas Frequentes (FAQ)

Acesse a seção de Perguntas Frequentes da brapi para esclarecer dúvidas sobre investimentos. Nossa FAQ fornece informações concisas, abordando tópicos relevantes para investidores, contribuindo para uma compreensão mais clara do mercado financeiro.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.